InvestorsHub Logo
Followers 15
Posts 999
Boards Moderated 0
Alias Born 12/13/2017

Re: markjohn62 post# 155063

Wednesday, 10/17/2018 9:28:00 PM

Wednesday, October 17, 2018 9:28:00 PM

Post# of 327999
We are not awaiting for full body clearance as I read it.

“Upon reviewing pre-submission information on the ActiPatch® back-pain study (https://clinicaltrials.gov/ct2/show/NCT03240146), the FDA provided positive feedback on the clinical results, and guidance on a 510(k) submission to obtain expanded market clearance for over-the-counter (OTC) treatment of musculoskeletal pain. This would make ActiPatch available as a drug-free, safe, pain relief option for the 126 million Americans (one in two adults) who are suffering with some form of musculoskeletal pain. While ActiPatch is already FDA cleared for treatment of pain from knee osteoarthritis (25 million) and plantar fasciitis (1 million annually), expanded market clearance would allow additional products for the back (42 million), neck (19 million), hip (9 million), shoulder (11 million), carpal tunnel (12 million) and many other musculoskeletal complaints.”

http://www.bielcorp.com/bioelectronics-receives-fda-pre-submission-approval-for-its-relief-of-musculoskeletal-pain-market-clearance-application/


We still would have to get clearance for Allay, migraine, or for other indications.

GLTA